Le Lézard
Classified in: Health
Subjects: RCL, PSF, CFG

Public advisory - Rhinaris Nasal Mist: One lot recalled due to risk of microbial growth which may lead to infection


OTTAWA, ON, July 7, 2023 /CNW/ -

Summary
Images
Affected products

Product

DIN

Lot

Expiry date

UPC

Rhinaris Nasal Mist 30 mL

02354551

230391A

31-05-2025

5760622302

Issue

The Pendopharm Division of Pharmascience Inc. is recalling one lot of Rhinaris Nasal Mist due to the risk of microbial growth. Using a product contaminated with microbes may lead to rhinosinusitis (a sinus infection). Children, pregnant people, seniors and people with weaker immune systems may be more susceptible to infection or complications from microbial contamination.

Rhinaris Nasal Mist is an over-the-counter drug used to moisturize and lubricate dry nasal passages  in adults and children at least two years of age. 

The company's testing showed that the preservative in the product may not be as effective as expected, which could lead to an increased risk of growth of microbes such as molds or bacteria over time if they are introduced into the product.

Although rare, rhinosinusitis can lead to more serious complications, such as nasal abscesses (a collection of pus), cellulitis (skin infection) or meningitis (infection and inflammation of the fluid and membranes surrounding the brain and spinal cord).

While the growth of other microbes may be possible, the testing showed that the preservative may not prevent the growth of a specific type of bacteria called Pseudomonas aeruginosa if it is introduced into the product. For someone whose immune system has been weakened by other serious conditions, especially cystic fibrosis, HIV/AIDS, severe lung disease, cancer, diabetes, or burns, Pseudomonas aeruginosa can cause serious infections including pneumonia, bone infections, urinary tract infections, gastrointestinal infections, meningitis, and blood infections.

What you should do

Également disponible en français

SOURCE Health Canada


These press releases may also interest you

at 05:50
NADclinic Group and Bontac Bio-Engineering (Shenzhen) Co., Ltd have officially entered into a dynamic strategic partnership to collaboratively focus on the future of global health and wellness. Synergistically leveraging their collective expertise...

at 05:35
Drug Farm announced today the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application of DF-003, a first-in-class, oral, potent, highly selective alpha-kinase 1 (ALPK1) inhibitor for clinical evaluation in...

at 05:02
'Companion Diagnostics: Technologies and Markets' is all about using special tests alongside certain medicines to figure out which treatment will work best for each person. These tests are called companion diagnostics because they go together with...

at 05:00
WellSync, an API-driven virtual care service provider, today announced its partnership with The Vitamin Shoppe to launch Whole Health Rx, a cutting-edge telehealth service providing access to GLP-1 medications for weight management. WellSync provides...

at 04:00
May 17, 2024 Three studies demonstrate how Philips MCOT wearable ambulatory monitoring ECG and proprietary AI models applied to ECG digital biomarkers can help to improve diagnosis, reduce readmissions, and lower costs Amsterdam, the Netherlands...

at 04:00
Brainomix, a pioneer in artificial intelligence (AI) imaging solutions to enable precision medicine, is proud to announce the FDA clearance of...



News published on and distributed by: